Related references
Note: Only part of the references are listed.Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman
Justin Thomas Low et al.
CNS oncology (2021)
H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model
Daniel Haag et al.
CANCER CELL (2021)
Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study
Yuan Wang et al.
FRONTIERS IN ONCOLOGY (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR
Philipp Sievers et al.
NEURO-ONCOLOGY (2021)
High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts
Alexandre Roux et al.
NEURO-ONCOLOGY (2020)
Nausea and Vomiting: a Palliative Care Imperative
Rita J. Wickham
CURRENT ONCOLOGY REPORTS (2020)
PET, image-guided HDAC inhibition of pediatric diffuse midline glioma improves survival in murine models
Umberto Tosi et al.
SCIENCE ADVANCES (2020)
Diffuse midline glioma: review of epigenetics
Tabitha M. Cooney et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Adult H3K27M-mutant diffuse midline glioma with gliomatosis cerebri growth pattern: Case report and review of the literature
Anudeep Yekula et al.
INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS (2020)
A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium
Sabine Mueller et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas
Karisa C. Schreck et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
A Rare High-Grade Glioma with a Histone H3 K27M Mutation in the Hypothalamus of an Adult Patient
Pin He et al.
WORLD NEUROSURGERY (2019)
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
Grant L. Lin et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2018)
H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis
Bette K. Kleinschmidt-DeMasters et al.
CLINICAL NEUROPATHOLOGY (2018)
Adult Brainstem Gliomas With H3K27M Mutation: Radiology, Pathology, and Prognosis
Elena V. Daoud et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
PATH-09. CLINICAL CHARACTERISTICS OF ADULTS WITH H3 K27M-MUTANT GLIOMAS AT UCSF
Robin Buerki et al.
NEURO-ONCOLOGY (2018)
Characteristics of H3 K27M-mutant gliomas in adults
David Meyronet et al.
NEURO-ONCOLOGY (2017)
Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models
Tammy Hennika et al.
PLOS ONE (2017)
Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations
David A. Solomon et al.
BRAIN PATHOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
FDA Approves New Agent for Multiple Myeloma
Marilyn P. Fenichel
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma
Eudocia Q. Lee et al.
NEURO-ONCOLOGY (2015)
FDA Approves New Agent for Multiple Myeloma
Marilyn P. Fenichel
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas
Denise Bechet et al.
ACTA NEUROPATHOLOGICA (2014)
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Peter Atadja
CANCER LETTERS (2009)
Share Paper
